OrganoClick Valuation
Is 0CF undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 0CF when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 0CF (€0.19) is trading above our estimate of fair value (€0.09)
Significantly Below Fair Value: 0CF is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 0CF?
Key metric: As 0CF is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 0CF's PS Ratio? | |
|---|---|
| PS Ratio | 1.9x |
| Sales | SEK 133.71m |
| Market Cap | SEK 259.03m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.3x |
| Enterprise Value/EBITDA | -65.5x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 0CF's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 0.7x | ||
BNN BRAIN Biotech | 1.2x | 8.5% | €69.9m |
BIG1 Bio-Gate | 0.9x | 16.3% | €6.3m |
NTG Nabaltec | 0.6x | 5.1% | €122.8m |
2HRA H&R GmbH KGaA | 0.1x | 3.0% | €128.4m |
0CF OrganoClick | 1.9x | 11.8% | €259.0m |
Price-To-Sales vs Peers: 0CF is expensive based on its Price-To-Sales Ratio (1.9x) compared to the peer average (0.7x).
Price to Sales Ratio vs Industry
How does 0CF's PS Ratio compare vs other companies in the DE Chemicals Industry?
Price-To-Sales vs Industry: 0CF is expensive based on its Price-To-Sales Ratio (1.9x) compared to the European Chemicals industry average (1x).
Price to Sales Ratio vs Fair Ratio
What is 0CF's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 1.9x |
| Fair PS Ratio | 0.3x |
Price-To-Sales vs Fair Ratio: 0CF is expensive based on its Price-To-Sales Ratio (1.9x) compared to the estimated Fair Price-To-Sales Ratio (0.3x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Compañía de Minas BuenaventuraA
US$3.0b
Engages in the exploration, development, construction, and operation of mineral processing business.
MBU
US$11.40
7D
-1.7%
1Y
36.5%
Mitsubishi Chemical Group
JP¥1.2t
Provides performance products, chemicals, industrial gases, health care products, and other products in Japan and internationally.
M3C
JP¥5.05
7D
0.9%
1Y
-12.1%
African Rainbow Minerals
R31.4b
Through its subsidiaries, operates as a diversified mining and minerals company in South Africa, Malaysia, and Switzerland.
EB9
R8.40
7D
-1.8%
1Y
-3.4%